Search PubMed⌕ Search

Biomedical subjects

Thomas L Petty

Publications and source records attributed to Thomas L Petty.

15 recordsLinked to original sources
PubMed2003

Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up.

BACKGROUND: Obstructive lung disease and lung cancer are tobacco-related diseases that can remain clinically silent until late in the disease process. We sought to define the risk for incident lung cancer among a national cohort of US adults with and without obstructive lung disease. METHODS: We studied participants in the First National Health and Nutrition Examination Survey, who had up to 22 years of follow-up. We classified subjects as having moderate or severe obstructive lung disease at baseline if the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) was less than 70% and the FEV1 was less than 80% of the predicted value. We also determined incident cases of lung cancer during the follow-up period. RESULTS: A total of 113 lung cancers occurred in the 5402 adults in the cohort. In the proportional hazards model adjusted for covariates of age, sex, race, education, smoking status, and duration and intensity of smoking, the presence of moderate or severe obstructive lung disease was associated with a higher risk for incident lung cancer (hazard ratio, 2.8; 95% confidence interval, 1.8-4.4). CONCLUSIONS: The presence of moderate or severe obstructive lung disease is a significant predictor of incident lung cancer in long-term follow-up. This finding may be useful clinically and in studies evaluating the utility of new tools for the early detection of lung cancer.

Adult↗
PubMed2003

Definition, epidemiology, course, and prognosis of COPD.

Chronic obstructive pulmonary disease (COPD) is now recognized as our nation's most rapidly growing health problem. It ranks as the 4th most common killer and is the only disease in the top 10 whose rank is rising. In 2000, more women than men (59,936 vs 59,118) died of COPD (1). The National Heart, Lung, and Blood Institute has calculated that in 2001, COPD was a $34.4 billion burden on society (both direct and indirect costs) (2). Two new initiatives, the National Lung Health Education Program (NLHEP) (3,4) and the Global Initiative for Chronic Obstructive Lung Disease (5), promote the early diagnosis and intervention of COPD. Both initiatives offer guidelines for the care of patients with all stages of COPD. The NLHEP recommends spirometry in all current or former smokers age > or = 45 years and anyone with symptoms of chronic cough, excessive dyspnea on exertion, or wheezing (6). "Test your lungs, know your numbers" is the motto of the NLHEP. Most patients with COPD are first seen by their primary care practitioner well before symptoms or signs of moderate-to-advanced stages of the disease are present. Thus, the primary care practitioner, working on the front line, is in the position to make a difference in the treatment and outcome of this devastating disorder.

Bronchodilator Agents↗
PubMed2003

Sputum cytology for the detection of early lung cancer.

Sputum cytology is an important step in the early diagnosis of roentgenographically occult lung cancer. It identifies primarily intraepithelial lesions, which are the most common squamous carcinomas not detected by helical CT. Patients at highest risk for lung cancer (eg, heavy smokers with airflow obstruction) should undergo sputum cytology. Patients with premalignant lesions (eg, moderate or severe dysplasia) and of course patients with carcinoma in situ or invasive carcinoma should receive fiberoptic bronchoscopy. The diagnosis and treatment of early-stage lung cancer usually has a favorable outcome. Today we have the knowledge and technology that can change the outcome of lung cancer through early identification, particularly in high-risk patients.

Biomarkers, Tumor↗
PubMed2003

Strategies in lung cancer detection. Achieving early identification in patients at high risk.

Screening can be crucial for timely identification of lung cancer and thus for early treatment and a favorable prognosis. This conclusion is true particularly for persons at high risk for lung cancer, including those exposed to asbestos or silicon dust. In this article, Drs Bechtel and Petty discuss the types of screening procedures available, their cost, and the approaches and timing that are most beneficial to the public as a whole.

Humans↗
PubMed2002

COPD: clinical phenotypes.

Different phenotypic presentations in advanced stages of COPD are less common than in years past because of therapies that alter the manifestations of disease. Early stages of COPD are often asymptotic, but may present as asthma, chronic bronchitis, emphysema or combinations. Unusual presentations at young age are not common, but may be dramatic.

Adolescent↗
PubMed2002

Diagnosis of roentgenographically occult lung cancer by sputum cytology.

The specialty has the knowledge and technology to change the outcome of lung cancer. Lung cancer, diagnosed in early stages, is as curable as all other cancers. Sputum cytology is the initial step in diagnosing roentgenographically occult lung cancer. Sputum cytology is complementary to CT scanning. Sputum cytology identifies small central lesions, and CT scanning discovers peripheral tiny adenocarcinomas.

Biomarkers, Tumor↗
PubMed2002

COPD in perspective.

In the last 200 years or so, the recognition, diagnosis, and understanding of the pathogenesis of COPD have evolved considerably. Over the past few decades, various definitions of COPD and its "components" also have developed. Despite this, however, the treatment options for patients with this relentlessly progressive disorder are relatively limited. In the mid-19th century, the introduction of the spirometer yielded a powerful tool for the diagnosis of COPD. The currently available small, cheap spirometers hold great promise to help patients and their physicians closely monitor lung function. Early recognition of the close associations among emphysema and, more recently, small airways disease, and impaired airflow is discussed. This review also stresses the importance of the identification of COPD in its initial stages and the early onset of appropriate treatment. The therapy for COPD has changed in the last 40 years. Drug therapies in the 1960s included potassium iodide and ephedrine. Corticosteroids were not used, and oxygen therapy and exercise were actually contraindicated. Modern therapy for COPD is now more systematic and includes the use of bronchodilators and corticosteroids to improve airflow, in addition to oxygen therapy, pulmonary rehabilitation and, in selected patients, lung volume reduction surgery. The causal link between the chronic inhalation of tobacco smoke and COPD is beyond doubt, and smoking cessation remains the most important goal for patients. It is hoped that new, more effective therapies will soon be available for the treatment of this disabling disorder to provide improvement in symptoms and patient quality of life and to reduce or stop the rate of disease progression and mortality in patients with COPD.

History, 19th Century↗
PubMed2002

John Hutchinson's mysterious machine revisited.

John Hutchinson, a surgeon, recognized that the volume of air that can be exhaled from fully inflated lungs is a powerful indicator of longevity. He invented the spirometer to measure what he called the vital capacity, ie, the capacity to live. Much later, the concept of the timed vital capacity, which became known as the FEV(1), was added. Together, these two numbers, vital capacity and FEV(1), are useful in identifying patients at risk of many diseases, including COPD, lung cancer, heart attack, stroke, and all-cause mortality. This article cites some of the rich history of the development of spirometry, and explores some of the barriers to the widespread application of simple spirometry in the offices of primary care physicians.

Diffusion of Innovation↗
PubMed2002

Performance of a new screening spirometer at a community health fair.

OBJECTIVE: Compare the results from a new screening spirometer (EasyOne) with the results from a standard laboratory spirometer (Vmax) approved by the American Thoracic Society. SETTING: A health fair at a community hospital. METHODS: We measured forced expiratory volume in the first second (FEV(1)) and forced expiratory volume in the first 6 seconds (FEV(6)). With the screening spirometer, good quality testing was achieved in 359 of 394 subjects (91%), and 115 subjects were also tested with the standard laboratory spirometer. The best test values for FEV(1) and FEV(6) were taken for 3 tests that agreed within 3%. FEV(6) was extrapolated from forced vital capacity on the printouts from the standard laboratory spirometer. RESULTS: Correlations between the screening spirometer results and the standard laboratory spirometer were excellent for FEV(1) (r = 0.93), FEV(6) (r = 0.96), and FEV(1)/FEV(6) (r = 0.72) (p = 0.001 for all comparisons). The 95% limits of agreement (mean difference between the 2 spirometers +/- 1.96 standard deviations) were: -0.18 and 0.69 for FEV(1); -0.24 and 0.81 for FEV(6); and -0.12 and 0.13 for FEV(1)/FEV(6). CONCLUSION: The new screening spirometer is suitable for clinical use.

Adult↗